Running First-in-human and Vaccines Studies in Australia
A US Investigational New Drug (IND) submission is not necessary to initiate first-in-human clinical trials in Australia. FIH trials in Australia are of high quality and are acceptable to other regulatory agencies in support of later Phase clinical trials.
The Australian Solution to expediting your GMO clinical trial
Learn more about expediting your clinical trials in Australia with a focus on GMO products.
Advancing oncology trials in Asia-Pacific
A growing number of biotechnology companies are looking at the Asia-Pacific region to run their clinical trials in oncology. While Australia and New Zealand are preferred locations to run early phase trials, sponsors often look at Asia for large late phase clinical studies.
Asia-Pacific – a Global hub for Hepatology Clinical Trials
Liver diseases are highly prevalent in the Asia-Pacific region. The region hosts some of the most active key opinion leaders and investigators with strong experience working with biotechnology companies on hepatology trials.
Clinical Trial Continuity in Asia-Pacific June 2020
Sites across the Asia-Pacific region have quickly changed how they manage trials, and most are able to deliver the clinical trial services their clients need. Biotech companies are currently initiating more clinical trials in Asia and Australia/New Zealand than in North America.